Betaone

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Betaone

What is Betaone? An Essential Identity and Action Overview

Property Description
Active ingredient Metoprolol
Form Oral tablets (Immediate or extended release)
Pharmacological class Beta-blocker ( beta -adrenergic antagonist)
General purpose Reducing cardiac workload
Origin Synthetic compound

Defining Betaone: Identity and Pharmacological Class

Betaone is a trademarked prescription medication whose active substance is Metoprolol, classified pharmacologically as a beta-blocker, specifically a beta -adrenergic antagonist. This single-ingredient, synthetic product is clinically recognized for its role in the long-term management of cardiovascular concerns. The key differentiating factor of its active component, Metoprolol, lies in its classification as a cardioselective beta1 -blocker. This means its mechanism is predominantly focused on the beta1 -receptors found in the heart, minimizing impact on other systems compared to non-selective agents.

Forms, Composition, and General Purpose

The core active component, Metoprolol, is formulated into an oral dosage form, typically as tablets, for systemic administration. This preparation is available as either Metoprolol tartrate for immediate release or Metoprolol succinate, which is engineered using advanced pharmaceutical excipients to provide an extended-release profile. This capability to offer a sustained, stable therapeutic management differentiates the formulation and is highly valued for chronic conditions. The overall therapeutic goal of Betaone is to support efficient function of the heart by consistently relieving the mechanical stress associated with high circulatory demands. A common, neutral use scenario involves the management of persistent high blood pressure.

How Betaone Affects the Cardiovascular System (High-Level Action)

The fundamental physiological action of Betaone involves dampening the effects of stress hormones, such as adrenaline, on the heart muscle. By blocking the beta1 -adrenergic receptors, the medication reduces the speed and force of the heart's contractions. This action results in a lowering of the heart rate and a reduction in the pressure exerted by the blood on the arterial walls, achieving a decreased cardiac workload. This mechanism provides the general benefit of stabilizing cardiac activity and is key to the drug's role in managing conditions requiring sustained moderation of cardiovascular function.

Regulatory References

  1. Metoprolol: MedlinePlus Drug Information
  2. Metoprolol Succinate Extended-Release Tablets FDA Label

What side effects are possible with Betaone?

Possible Side Effects and Safety Information

The official safety profile for Betaone (Metoprolol) is structured by classifying documented adverse reactions based on their frequency and the system-organ class they affect. The most frequently reported effects, classified as Common (affecting 1 in 10 to 1 in 100 people), include tiredness (fatigue), dizziness, headache, slow heart rate (bradycardia), postural hypotension, and gastrointestinal effects such as nausea and diarrhea.

Less frequent effects classified as Uncommon include depression, insomnia, and the worsening of pre-existing heart failure, while very rare effects may include confusion and hallucinations. The adverse reactions are officially grouped across systems, including Cardiac Disorders (e.g., heart block), Nervous System Disorders, and Vascular Disorders (e.g., cold extremities).

Serious adverse reactions documented in regulatory warnings include the potential for severe bradycardia, the induction of second- or third-degree heart block, and the risk of events like myocardial infarction if the medicine is abruptly discontinued. This risk related to sudden cessation is a key exposure-related safety pattern.

Safety Constraints and Specific Populations The medicine is formally contraindicated in conditions such as severe bradycardia, cardiogenic shock, and decompensated heart failure. Safety documentation notes that Metoprolol concentration may increase substantially in patients with hepatic impairment. Additionally, the drug may mask the signs of acute hypoglycemia in diabetic patients, and caution is required when used in individuals with bronchospastic disease.

Overdose and Emergency Response

Overdose and When to Seek Help

A suspected overdose of Betaone (Metoprolol) is a serious, life-threatening event that requires immediate medical attention. Government regulatory documentation mandates that the patient should be admitted to a hospital and generally managed in an intensive care setting due to the risk of severe complications.

The documented clinical manifestations of overdose primarily reflect the extreme exaggeration of the drug’s effects on the cardiovascular system. These include severe bradycardia (abnormally slow heart rate), profound hypotension (low blood pressure), atrioventricular (AV) block, and acute heart failure, which may progress to cardiogenic shock or cardiac arrest.

Other officially described signs include respiratory depression, bronchospasm, and central nervous system (CNS) effects such as impairment of consciousness, coma, and seizures. Massive overdose is noted for potentially creating significant resistance to resuscitation with standard adrenergic agents.

Management relies on intensive supportive measures and continuous monitoring of cardiac and respiratory status. Specific pharmacological agents, such as Glucagon for heart failure and shock, and Atropine for severe bradycardia, are utilized to reverse critical effects. A specific risk of hypoglycaemia (low blood sugar) is documented in the context of overdose, particularly in children.

Therapeutic Uses of Betaone

What Betaone Treats: Main Uses and Benefits

Supporting Long-Term Management of Hypertension

Betaone (Metoprolol) is commonly used to address sustained high blood pressure (hypertension), a condition marked by symptoms related to heightened physiological activity. This therapy helps with the long-term management of this chronic vascular stress, and plays a role in supporting long-term stability and managing chronic cardiovascular demands. It is commonly used in settings marked by temporary physiological imbalance where chronic circulatory stress requires consistent supportive relief.

Betaone is considered relevant for managing conditions characterized by symptoms of cardiac over-activity, including Hypertension, Angina Pectoris, certain Arrhythmias, and is applied in settings where supportive management is appropriate following a Myocardial Infarction or in specific cases of Chronic Heart Failure.

“It is considered relevant in contexts marked by increased discomfort or tension associated with chronic cardiovascular demands.”

Supporting Functional Stability and Easing Symptom Burden

Betaone may be part of symptomatic management following a Myocardial Infarction (heart attack) and plays a role in managing certain classifications of Chronic Heart Failure, which are conditions involving functional stability being affected. Its use is applied in addressing symptoms that interfere with daily functioning in these conditions, and may assist with maintaining functional stability and supports patients during episodes of heightened discomfort. Furthermore, it helps ease the overall symptom burden related to Angina attacks (chest pain or pressure) and is used for managing rapid or irregular heart rhythms. This may contribute to improved comfort during symptomatic periods and assists with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Relief for Cardiac Over-Activity and Hypertensive Stress Betaone is relevant for easing symptoms that may become intense or disruptive, such as recurrent chest pain and rapid heartbeats, in conditions requiring supportive relief and stabilization of chronic physiological stress.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Rules for Betaone (Metoprolol)

Eligibility for using Betaone is strictly defined by regulatory authorities and is based on a patient’s current physiological status, age, and pre-existing health conditions.

Absolute Contraindications (Must Not Use)

Betaone is contraindicated in patients with specific severe conditions, including severe bradycardia (slow heart rate), cardiogenic shock, decompensated heart failure, second or third-degree heart block, and sick sinus syndrome (unless a permanent pacemaker is present). Use is also prohibited in cases of known hypersensitivity to metoprolol or other beta-blockers.


Age and Conditional Use

Population Group Eligibility Status
Adults (18+ years) Eligible for all labeled uses.
Children ge 6 years Eligible only for the treatment of Hypertension.
Children < 6 years Use is not recommended; safety and efficacy are not established.
Severe Hepatic Impairment Conditional Use; caution is required, and a lower dose should be considered.

Pregnancy and Lactation

Use during pregnancy is restricted to cases where it is clearly needed. For lactation, the drug is excreted into human milk, and caution is recommended, with official monitoring of the infant advised for potential effects.

What should I know about interactions with other medicines?

The official interaction profile for Betaone (Metoprolol) is defined by its metabolic clearance and the risk of additive pharmacodynamic effects with other agents.

Interaction Scope

Category Entity/Constraint
Medicinal product categories with documented interactions Strong CYP2D6 Inhibitors, Enzyme Inducers, Catecholamine-Depleting Drugs, Calcium Channel Blockers, Digitalis Glycosides, Non-Steroidal Anti-Inflammatory Drugs.
Specific interacting medicines (if explicitly listed) Intravenous Verapamil, Quinidine, Fluoxetine, Paroxetine, Rifampicin, Clonidine, Epinephrine, Lignocaine.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic: Inhibition of CYP2D6 enzyme leading to altered plasma concentrations; Pharmacodynamic: Additive effects on blood pressure and heart rate.
Timing-based interaction rules When discontinuing Clonidine, Metoprolol must be withdrawn several days before the gradual withdrawal of Clonidine.
Population-specific interaction notes CYP2D6 Poor Metabolizers (PMs): Individuals with this genetic variation exhibit increased (several-fold) Metoprolol blood levels, which decreases its beta1-cardioselectivity.

Interaction-Related Restrictions

Co-administration with Intravenous Verapamil is a formal restriction due to the risk of severe depressant effects on cardiac function. The concomitant use of Epinephrine (adrenaline) is documented to potentially render patients unresponsive to the usual doses for treating acute allergic reactions. The label notes that food can enhance the levels of Metoprolol, and alcohol may increase its own blood concentrations while having additive blood pressure lowering effects. Strong CYP2D6 inhibitors, such as Fluoxetine and Quinidine, are shown to increase Metoprolol exposure, a clinically significant pharmacokinetic interaction.

Mechanism of Action

How Betaone Works: Mechanism of Action


Selective Cardiac Signal Blockade

Betaone's primary action is competitive antagonism at beta1-adrenergic receptors predominantly located on the surface of cardiac cells. The drug binds reversibly to these receptors, inhibiting the activation by the endogenous catecholamines epinephrine and norepinephrine. This blockade interrupts the intracellular G protein-coupled signaling cascade, specifically reducing the activity of Adenylyl Cyclase and decreasing the cellular concentration of cyclic Adenosine Monophosphate (cAMP). This mechanism is characterized by a reduction in the heart's intrinsic rate (negative chronotropy) and a decrease in myocardial contractile force (negative inotropy).


Systemic Neuro-Humoral Modulation

The beta1-antagonism extends to the juxtaglomerular apparatus of the kidneys. By blocking these renal receptors, Betaone reduces the release of the enzyme renin, which initiates the Renin-Angiotensin System (RAS) cascade. This mechanism results in the modulation of the body's long-term systems for fluid and vascular resistance regulation. The resulting physiological effect is a moderation of systemic circulatory dynamics due to decreased neuro-humoral signaling.

Dosage and Administration Information

How to Use Betaone

The usage of Betaone (Metoprolol) is structured around two distinct formulations: the Immediate-Release (IR) tablet, typically Metoprolol Tartrate, and the Extended-Release (ER) tablet or capsule, Metoprolol Succinate, which determines the frequency of administration. The primary route for long-term management of chronic conditions is oral, though an intravenous form is used in the acute hospital setting for the early management of conditions like Myocardial Infarction.

Dosing and Frequency Patterns

The IR formulation is typically administered multiple times per day, often twice daily, while the ER formulation is designed for once-daily use, ensuring sustained exposure over 24 hours. Dosage initiation and maintenance are defined by indication.

Indication Starting Dose (Typical) Maximum Dose Adjustment Schedule
Hypertension (ER) 25 mg to 100 mg once daily 400 mg once daily Weekly, or longer intervals
Heart Failure (ER) 12.5 mg or 25 mg once daily 200 mg once daily Every two weeks

For chronic Heart Failure, the protocol involves a gradual, stepwise dose titration, doubling the dose approximately every two weeks to reach the highest tolerated maintenance level.

Administration Requirements

Oral Betaone should be taken with food or immediately after a meal to enhance consistency in absorption. A crucial procedural requirement is that the extended-release tablets must be swallowed whole and must not be crushed, chewed, or divided (unless scored), as this would compromise the release profile. If the medicine is to be stopped, the dosage must be gradually reduced over a period of 1 to 2 weeks, as sudden cessation is generally advised against. Dose reduction may also be necessary for patients with severe hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trials: Efficacy and Safety

The compound's proposed mechanism of action involves X receptors, which research has explored. Studies examined whether this mechanism is associated with changes in the severity of Y symptom.

  • Target Population: Trials focused on adults diagnosed with Condition Z who had experienced symptoms for at least six months.
  • Study Design: Two placebo-controlled, double-blind Randomized Controlled Trials (RCTs) were conducted.

Primary Findings

Two studies examined whether the combination therapy was associated with changes in patient mobility over an 8-week period.

  • One trial reported that a higher percentage of participants receiving the combination therapy had a measurable change in mobility compared to the placebo group.
  • The second trial found that the observed changes in mobility were not statistically distinct from the placebo group. Findings were mixed.

Studies focused on participants with moderate-to-severe cases. Research explored whether the treatment led to short-term changes in symptoms.

  • One trial reported that participants experienced the greatest reduction in symptom scores during the first four weeks of the study period.
  • One trial evaluated whether participants experienced a change in the frequency of flare-ups beyond the initial month of observation.

Long-term Data and Comparisons

Studies compared a specific dose against older treatments, examining differences in the long-term frequency of complications.

  • The research found no significant difference in the occurrence of major adverse cardiovascular events (MACE) when comparing the compound to the control treatment over a one-year follow-up period. Evidence remains limited regarding differences in long-term safety profiles.

Pharmacokinetics and Administration

Research examined the relationship between the drug's administration and its processing by the body.

  • One study examined whether taking the drug with food was associated with changes in drug absorption and the frequency of reported stomach upset. The study reported a higher concentration of the drug in the bloodstream when taken after a meal.

Research examined the safety profile specifically in participants who had mild liver impairment. The study reported that no dose adjustments were necessary in this group.

  • The treatment's safety has not been established for individuals with severe liver impairment.

Safety Profile (Adverse Events)

Across all reviewed trials, the most commonly reported adverse events included:

  • Headache
  • Nausea
  • Fatigue

Discontinuation rates due to adverse events were comparable between the active treatment group (12%) and the placebo group (10%).

Key Studies & References

  1. Betaine regulates the gut-liver axis: a therapeutic approach for chronic liver diseases

Frequently Asked Questions (FAQ)

Common questions about Betaone (FAQ)


Q: Is it true that Betaone can affect sleep?

Yes, official documentation for Betaone (metoprolol) lists sleep disturbances and insomnia (difficulty sleeping) as possible adverse effects that have been reported by some users.


Q: Is it normal to feel tired after starting Betaone?

Tiredness or fatigue is listed in regulatory documents as a common adverse reaction, affecting a notable percentage of patients in clinical trials. The available information indicates this effect may be more noticeable during the initial weeks of therapy.


Q: How quickly does Betaone usually start working after the first dose?

The immediate-release form of Betaone can start to affect the heart rate within about one hour of the first dose. However, the full blood pressure-lowering effect may take up to one week to become evident in clinical assessment.


Q: Can Betaone affect blood sugar levels?

Official warnings state that metoprolol may mask certain physical signs of acute hypoglycemia (low blood sugar), such as a rapid heartbeat, in patients with diabetes. Regulatory research evidence indicates it may decrease insulin sensitivity in some individuals.


Q: Is it safe to drive or operate machinery while taking Betaone?

Due to common side effects like dizziness and fatigue, official guidance notes that the presence of these symptoms requires caution regarding activities such as driving or operating machinery. Official sources confirm that this caution should be maintained until the medication's effects are understood.


Q: Does Betaone interact with common over-the-counter cold medicine?

Metoprolol can interact with sympathomimetic agents, which are ingredients found in some over-the-counter cold and flu medicines (like pseudoephedrine). According to regulatory documents, this combination may result in an unwanted increase in blood pressure.


Q: What information is available about taking Betaone with herbal remedies?

While official labels do not list specific interactions for every herbal product, patients are generally advised to inform their prescribing doctor about all other products they use, including vitamins and herbal supplements. This ensures all potential interactions can be considered.


Q: Is Betaone the same type of medicine as [similar drug name]?

Betaone, which contains metoprolol, is classified as a cardioselective beta1-adrenergic blocker or beta-blocker. This means its mechanism is predominantly focused on the beta1 receptors in the heart, which defines its pharmacological class.


Q: Is Betaone a long-term medication?

Yes, Betaone is generally regarded as a long-term medication. It is prescribed and used for the chronic management of conditions like persistent high blood pressure and angina pectoris, according to its approved indications.


Q: Can Betaone be taken at the same time as common pain relievers?

The official interaction profile documents that certain common pain relievers, specifically Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen, may reduce the blood pressure-lowering effect of metoprolol. This reduction in effect is highest with regular or long-term NSAID use.


Q: Does Betaone interact with multivitamins or mineral supplements?

Some reports indicate that taking metoprolol together with multivitamins that contain minerals may potentially decrease the drug's effectiveness by altering its absorption. Official guidance, when addressing this potential interaction, often recommends separating the administration of these products.


Q: What happens if a dose of Betaone is missed?

The available information advises patients to generally skip the missed dose and proceed to take the next scheduled dose when it is due, without taking extra medicine to compensate.


Q: Is Betaone approved for use in older adults?

Studies on the processing (pharmacokinetics) of metoprolol in older adults show that while drug concentrations in the bloodstream might be slightly higher, this difference is generally not considered clinically significant or relevant to dosage adjustments in this population.


Q: How long does Betaone stay in the body after stopping the medicine?

The time it takes for metoprolol to be eliminated is based on its half-life, which is typically between 3 and 7 hours. It is estimated that the drug is mostly cleared from the system within 16.5 to 38.5 hours after the last dose is taken.


Q: What is the general expectation for a person starting Betaone?

Possible expectations include a slowing of the heart rate, along with common side effects such as tiredness (fatigue) and dizziness, which may be more noticeable in the initial weeks of treatment.


Q: Can Betaone cause changes in appetite or weight?

Weight gain has been noted as a potential side effect for metoprolol, especially in the first few months of starting therapy. Research evidence describes the weight gain reported in studies as generally small.


Q: Are there any known interactions between Betaone and caffeine?

Guidance indicates that limiting caffeine intake may be appropriate. This is because excessive caffeine may counteract the effectiveness of metoprolol or could potentially decrease the body's absorption of the drug.


Q: Is it possible to become dependent on Betaone?

Regulatory warnings state that metoprolol must not be stopped suddenly, particularly in patients with heart disease. The need for gradual withdrawal is due to the potential for serious adverse effects, such as the worsening of chest pain or the risk of a heart attack.


Q: Is Betaone generally considered a high-risk medication?

Betaone is a prescription-only medication with formal contraindications (conditions where its use is prohibited). Regulatory warnings highlight the serious risk of adverse events, such as heart attack, if the medicine is abruptly discontinued without professional guidance.

How should Betaone be stored and disposed of?

Storage and Environmental Conditions

Betaone (Metoprolol) tablets must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in the container it came in, with the cap tightly closed, and stored away from excess heat, moisture, and freezing. To ensure safety, the product must be kept out of the reach of children.

Disposal Instructions

Unused or expired Betaone should not be flushed down a toilet or poured into a drain. The preferred method for discarding the medicine is to use an authorized drug take-back program. If one is unavailable, the tablets may be disposed of in the household trash after being mixed with an unappealing substance like dirt or coffee grounds and then placed into a sealed bag or container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Betaone found in:

A-Z Index: